莫西沙星联合头孢氨苄治疗老年呼吸道感染患者的临床疗效研究  

Study on clinical efficacy of moxifloxacin combined with cephalexin in the treatment of elderly patients with respiratory tract infection

作　　者：吕涛 LYU Tao(Department of Pharmacy,Community Health Service Center,Kouzhen Street,Laiwu District,Jinan 271100,China)

机构地区：[1]济南市莱芜区口镇街道社区卫生服务中心药剂科,271100

出　　处：《中国实用医药》2025年第7期72-75,共4页China Practical Medicine

摘　　要：目的探究老年呼吸道感染患者治疗中联合使用头孢氨苄与莫西沙星的临床效果。方法抽取老年呼吸道感染患者85例,随机分为对照组(n=42)与研究组(n=43)。对照组患者使用头孢氨苄治疗,研究组患者联合使用头孢氨苄与莫西沙星治疗。对比两组患者症状消失时间、肺功能指标、炎性因子水平、治疗效果以及不良反应发生情况。结果研究组患者体温恢复时间、咳嗽消失时间、肺部啰音消失时间及白细胞恢复时间分别为(3.21±1.54)、(3.86±2.40)、(4.62±1.33)、(4.96±2.74)d,均比对照组的(4.96±2.67)、(6.81±4.69)、(6.72±2.65)、(7.51±2.88)d更早,统计学差异明显(P<0.05)。研究组患者治疗总有效率95.35%比对照组的76.19%明显更高,统计学差异明显(P<0.05)。研究组患者治疗后C反应蛋白(CRP)(5.67±0.61)mg/L、降钙素原(PCT)(5.87±0.51)ng/ml、白细胞介素-6(IL-6)(41.49±2.37)ng/L、白细胞计数(WBC)(8.24±1.01)×10^(9)/L显著低于对照组的(8.71±0.72)mg/L、(7.62±0.80)ng/ml、(51.58±3.24)ng/L、(11.36±1.34)×10^(9)/L,统计学差异明显(P<0.05)。研究组患者治疗后第1秒用力呼气容积(FEV1)(2.89±0.41)L、用力肺活量(FVC)(3.17±0.52)L及第1秒用力呼气容积与用力肺活量的比值(FEV1/FVC)(80.05±7.94)%均显著高于对照组的(2.42±0.32)L、(2.82±0.43)L、(71.94±6.92)%,统计学差异明显(P<0.05)。研究组患者不良反应发生率与对照组对比没有显著差异(P>0.05)。结论在老年呼吸道感染患者治疗中应用头孢氨苄联合莫西沙星能够有效改善患者肺功能、炎性因子水平,有利于缓解临床症状,且安全性高。Objective To explore the clinical effect of moxifloxacin combined with cephalexin in the treatment of elderly patients with respiratory tract infection.Methods 85 elderly patients with respiratory tract infection were randomly divided into control group(n=42)and study group(n=43).The control group was treated with cephalexin,and the study group was treated with cefalexin and moxifloxacin.The time of symptom resolution,lung function index,inflammatory factor level,therapeutic effect and occurrence of adverse reactions were compared between the two groups.Results The recovery time of body temperature,cough disappearance time,disappearance time of lung rales and recovery time of white blood cell were(3.21±1.54),(3.86±2.40),(4.62±1.33)and(4.96±2.74)d in the study group,which were shorter than(4.96±2.67),(6.81±4.69),(6.72±2.65)and(7.51±2.88)d in the control group,and the difference was statistically significant(P<0.05).The total effective rate of 95.35%in the study group was significantly higher than 76.19%in the control group,and the difference was statistically significant(P<0.05).After treatment,the study group had C-reactive protein(CRP)of(5.67±0.61)mg/L,procalcitonin(PCT)of(5.87±0.51)ng/ml,interleukin-6(IL-6)of(41.49±2.37)ng/L and white blood cell count(WBC)of(8.24±1.01)×10^(9)/L,which were significantly lower than(8.71±0.72)mg/L,(7.62±0.80)ng/ml,(51.58±3.24)ng/L and(11.36±1.34)×10^(9)/L in the control group,and the difference was statistically significant(P<0.05).After treatment,the study group had forced expiratory volume in one second(FEV1)of(2.89±0.41)L,forced vital capacity(FVC)of(3.17±0.52)L and FEV1/FVC of(80.05±7.94)%,which were significantly higher than(2.42±0.32)L,(2.82±0.43)L and(71.94±6.92)%in the control group,and the statistical difference was significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the study group and the control group(P>0.05).Conclusion The application of cephalexin combined with moxifloxacin in the treatment of

关 键 词：莫西沙星 头孢氨苄 呼吸道感染 肺功能 老年 

分 类 号：R56[医药卫生—呼吸系统]